$RYTM
RHYTHM PHARMACEUTICALS, INC.

2021 Q4 Form 10-Q Financial Statement

#000155837021014043 Filed on November 02, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $1.817M $1.028M $0.00
YoY Change
Cost Of Revenue $236.0K $222.0K
YoY Change
Gross Profit $1.581M $806.0K
YoY Change
Gross Profit Margin 87.01% 78.4%
Selling, General & Admin $21.00M $17.51M $11.29M
YoY Change 60.03% 55.08% 7.16%
% of Gross Profit 1328.02% 2172.08%
Research & Development $31.57M $27.54M $23.00M
YoY Change 43.85% 19.76% -13.46%
% of Gross Profit 1997.09% 3416.75%
Depreciation & Amortization $325.0K $315.0K $170.0K
YoY Change 80.56% 85.29% -10.53%
% of Gross Profit 20.56% 39.08%
Operating Expenses $52.57M $45.05M $34.28M
YoY Change 49.9% 31.39% -7.61%
Operating Profit -$50.99M -$44.24M -$34.28M
YoY Change 29.04% -7.61%
Interest Expense $134.0K $138.0K $470.0K
YoY Change -25.56% -70.64% -57.27%
% of Operating Profit
Other Income/Expense, Net $0.00 $138.0K $466.0K
YoY Change -70.39% -57.79%
Pretax Income -$50.86M -$44.10M -$33.82M
YoY Change 45.72% 30.4% -6.06%
Income Tax -$7.989M -$8.995M
% Of Pretax Income
Net Earnings -$42.87M -$35.11M -$33.82M
YoY Change 22.83% 3.81% -6.07%
Net Earnings / Revenue -2359.16% -3415.08%
Basic Earnings Per Share -$0.70
Diluted Earnings Per Share -$852.6K -$698.7K -$766.2K
COMMON SHARES
Basic Shares Outstanding 50.27M 50.23M 44.12M
Diluted Shares Outstanding 50.25M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $294.9M $328.4M $201.8M
YoY Change 70.63% 62.71% 24.26%
Cash & Equivalents $59.25M $92.37M $67.67M
Short-Term Investments $235.6M $236.0M $134.1M
Other Short-Term Assets $4.103M $7.282M $8.100M
YoY Change 34.61% -10.1% -3.57%
Inventory $111.0K
Prepaid Expenses
Receivables $1.025M
Other Receivables $0.00
Total Short-Term Assets $308.4M $335.6M $209.9M
YoY Change 69.75% 59.89% 22.83%
LONG-TERM ASSETS
Property, Plant & Equipment $2.813M $2.956M $3.289M
YoY Change -11.96% -10.12% -45.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.14M $10.86M $400.0K
YoY Change 2935.75% 2615.25% -42.86%
Total Long-Term Assets $21.14M $20.19M $5.563M
YoY Change 291.05% 262.88% -15.71%
TOTAL ASSETS
Total Short-Term Assets $308.4M $335.6M $209.9M
Total Long-Term Assets $21.14M $20.19M $5.563M
Total Assets $329.5M $355.8M $215.5M
YoY Change 76.15% 65.13% 21.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.737M $4.614M $3.793M
YoY Change 17.08% 21.65% -50.74%
Accrued Expenses $30.08M $18.27M $11.54M
YoY Change 139.54% 58.33% -34.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.43M $23.47M $15.85M
YoY Change 141.34% 48.08% -37.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.945M $2.104M $2.700M
YoY Change -25.19% -22.07% -15.63%
Total Long-Term Liabilities $1.945M $2.104M $2.700M
YoY Change -25.19% -22.07% -15.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.43M $23.47M $15.85M
Total Long-Term Liabilities $1.945M $2.104M $2.700M
Total Liabilities $45.37M $33.56M $18.54M
YoY Change 120.84% 81.01% -34.72%
SHAREHOLDERS EQUITY
Retained Earnings -$528.9M -$486.1M -$424.4M
YoY Change 15.16% 14.52%
Common Stock $50.00K $50.00K $44.00K
YoY Change 13.64% 13.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $284.2M $322.3M $196.9M
YoY Change
Total Liabilities & Shareholders Equity $329.5M $355.8M $215.5M
YoY Change 76.15% 65.13% 21.4%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$42.87M -$35.11M -$33.82M
YoY Change 22.83% 3.81% -6.07%
Depreciation, Depletion And Amortization $325.0K $315.0K $170.0K
YoY Change 80.56% 85.29% -10.53%
Cash From Operating Activities -$40.47M -$40.16M -$27.03M
YoY Change 38.98% 48.58% -19.58%
INVESTING ACTIVITIES
Capital Expenditures -$68.00K -$106.0K -$130.0K
YoY Change -15.0% -18.46% -50.0%
Acquisitions
YoY Change
Other Investing Activities $7.316M $62.89M $35.04M
YoY Change -88.2% 79.47% -16.03%
Cash From Investing Activities $7.248M $62.78M $34.91M
YoY Change -88.29% 79.83% -15.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 413.0K 700.0K
YoY Change -76.19% -41.0% 0.0%
NET CHANGE
Cash From Operating Activities -40.47M -40.16M -27.03M
Cash From Investing Activities 7.248M 62.78M 34.91M
Cash From Financing Activities 100.0K 413.0K 700.0K
Net Change In Cash -33.12M 23.03M 8.580M
YoY Change -199.8% 168.45% 0.23%
FREE CASH FLOW
Cash From Operating Activities -$40.47M -$40.16M -$27.03M
Capital Expenditures -$68.00K -$106.0K -$130.0K
Free Cash Flow -$40.40M -$40.05M -$26.90M
YoY Change 39.13% 48.9% -19.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38223
dei Entity Registrant Name
EntityRegistrantName
RHYTHM PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001649904
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50268312
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44235903
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2159271
dei Entity Address Address Line1
EntityAddressAddressLine1
222 Berkeley Street
dei Entity Address Address Line2
EntityAddressAddressLine2
12th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
264-4280
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
RYTM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50268312
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92372000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100854000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
235982000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
71938000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7282000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8876000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
335636000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
181668000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2956000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3195000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1598000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1807000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4772000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
328000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
403000
CY2021Q3 us-gaap Other Long Term Investments
OtherLongTermInvestments
10533000
CY2021Q3 us-gaap Assets
Assets
355823000
CY2020Q4 us-gaap Assets
Assets
187073000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4614000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4900000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18265000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12559000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
588000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
535000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23467000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17994000
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7989000
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2104000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2551000
CY2021Q3 us-gaap Liabilities
Liabilities
33560000
CY2020Q4 us-gaap Liabilities
Liabilities
20545000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355823000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
187073000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17507000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11289000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47490000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50268312
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44235903
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
50000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
808265000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
625762000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
49000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-486073000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-459327000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
322263000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
166528000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1028000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1337000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
222000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
363000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27539000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22995000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72554000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68496000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33006000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
45268000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
34284000
us-gaap Costs And Expenses
CostsAndExpenses
120407000
us-gaap Costs And Expenses
CostsAndExpenses
101502000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-44240000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34284000
us-gaap Operating Income Loss
OperatingIncomeLoss
-119070000
us-gaap Operating Income Loss
OperatingIncomeLoss
-101502000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
100000000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
138000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
466000
us-gaap Investment Income Interest
InvestmentIncomeInterest
313000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2403000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
138000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
466000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
100313000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2403000
CY2021Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-44102000
CY2020Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-33818000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-18757000
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-99099000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8995000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7989000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-35107000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-33818000
us-gaap Net Income Loss
NetIncomeLoss
-26746000
us-gaap Net Income Loss
NetIncomeLoss
-99099000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.77
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.25
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50246303
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44142334
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49374336
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44097178
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-35107000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-33818000
us-gaap Net Income Loss
NetIncomeLoss
-26746000
us-gaap Net Income Loss
NetIncomeLoss
-99099000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-392000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-107000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
238000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35107000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34210000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26853000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-98861000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
166528000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5191000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
388000
CY2021Q1 rytm Stock Issued During Period Value Stock Options And Restricted Stock Units Vesting
StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsVesting
3466000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161731000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-107000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
43750000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
380947000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5669000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
383000
CY2021Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
79000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-35389000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
351689000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5268000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
233000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
180000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-35107000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
322263000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
281020000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5475000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
324000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
383000
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
63000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-34164000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
253101000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
501000
CY2020Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-392000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
512000
rytm Deferred Rent Expense
DeferredRentExpense
-185000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3028000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
174000
CY2020Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
567000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-31117000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
225753000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4695000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
198000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-33818000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
196937000
us-gaap Profit Loss
ProfitLoss
-26746000
us-gaap Profit Loss
ProfitLoss
-99100000
us-gaap Share Based Compensation
ShareBasedCompensation
16128000
us-gaap Share Based Compensation
ShareBasedCompensation
13198000
rytm Gain On Sale Of Priority Review Voucher
GainOnSaleOfPriorityReviewVoucher
100000000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
7989000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
833000
rytm Deferred Rent Expense
DeferredRentExpense
-173000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1591000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1092000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
10533000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5392000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-8387000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-105531000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-92858000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
456238000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
53398000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
292197000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
150172000
rytm Proceeds From Sale Of Priority Review Voucher
ProceedsFromSaleOfPriorityReviewVoucher
100000000
rytm Milestone Obligation Under License Agreement
MilestoneObligationUnderLicenseAgreement
5000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
366000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
130000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-69407000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
96644000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161731000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4029000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1067000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
621000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
522000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
166381000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1589000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8557000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5375000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
101257000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
62697000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
92700000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68072000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Rhythm Pharmaceuticals, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><span style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><span style="display:inline-block;width:20.86%;"> </span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Notes to Unaudited Condensed Consolidated Financial Statements</b></span><span style="display:block;height:1px;position:absolute;width:100%;z-index:0;">‌</span><span style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (In thousands, except share and per share information)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rhythm Pharmaceuticals, Inc. (the “Company” or “we”) is a commercial-stage biopharmaceutical company focused on changing the paradigm for the treatment of rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger or hyperphagia.  Our lead product candidate is IMCIVREE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (setmelanotide), a potent melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic diseases of obesity. We believe IMCIVREE, for which we have exclusive worldwide rights, has the potential to restore dysfunctional MC4R signaling due to impaired MC4R pathway function. MC4R pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. IMCIVREE has been approved by the U.S. Food and Drug Administration, or FDA, for chronic weight management in adult and pediatric patients six years of age and older with obesity due to proopiomelanocortin, or POMC, proprotein convertase subtilisin/kexin type 1, or PCSK1, or leptin receptor, or LEPR, deficiency confirmed by genetic testing.  IMCIVREE also has been approved by the European Commission  for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. IMCIVREE is now commercially available in the United States, and we are pursuing an international strategy to establish access and reimbursement for IMCIVREE in the European Union, or EU, and Great Britain.  We also have completed and submitted a supplemental New Drug Application, or sNDA, to the U.S. Food and Drug Administration or FDA, and a Type II variation marketing authorization application, or MAA, to the EMA for IMCIVREE for the treatment of obesity and control of hunger in adult and pediatric patients 6 years of age and older with Bardet-Biedl syndrome, or BBS, or Alström syndrome.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a Delaware corporation organized in February 2013 under the name Rhythm Metabolic, Inc., and as of October 2015, under the name Rhythm Pharmaceuticals, Inc. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s continued development efforts are focused on obesity related to several single gene-related, or monogenic, MC4R pathway deficiencies: Bardet-Biedl and Alstrom syndromes; obesity due to a genetic variant in one of the two alleles of the POMC, PCSK1 or LEPR gene, or heterozygous POMC, PCSK1 or LEPR obesity (collectively HETs); obesity due to steroid receptor coactivator 1, or SRC1, deficiency; obesity due to SH2B adapter protein 1, or SH2B1, deficiency; hypothalamic obesity; and MC4R deficiency obesity.  In addition, we have expanded our development program to explore setmelotide’s potential efficacy in patients with severe obesity which may be due to variants in an additional 31 genes that are related to the MC4R pathway.  There are additional diseases being studied as part of investigator-initiated protocols. Currently, there are no effective or approved treatments for these MC4R pathway-related diseases. The Company believes that the MC4R pathway is a compelling target for treating these genetic diseases because of its critical role in regulating appetite and weight by promoting satiety and weight control, and that peptide therapeutics are uniquely suited for activating this target. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"> <span style="background-color:#ffffff;">The Company is subject to risks and uncertainties common to commercial-stage companies in the biotechnology industry, including but not limited to risks associated with the commercialization of approved products, completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Commercialization of approved products will require significant resources and in order to market IMCIVREE, the Company must continue to build its sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred operating losses and negative cash flows from operations since inception.  As of September 30, 2021, the Company had an accumulated deficit of $486,073.  The Company has primarily funded these losses through the proceeds from the sales of common and preferred stock, asset sales as well as capital contributions received from the former parent company, Rhythm Holdings LLC. To date, the Company has minimal product revenue and management expects operating losses to continue for the foreseeable future. The Company has devoted substantially all of its resources to its drug development efforts, comprising of research and development, manufacturing, conducting clinical trials for its product candidates, protecting its intellectual property, pre-commercialization activities and general and administrative functions relating to these operations. The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Company completed the sale of a Rare Pediatric Disease Priority Review Voucher, or PRV, that it received in connection with the approval of IMCIVREE for $100,000. As the PRV did not have a carrying value, the gain recognized within Other income (loss) was equal to the gross proceeds received, with costs related to the sale of the voucher recorded within selling, general and administrative expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At September 30, 2021, the Company had $328,354 of cash and cash equivalents and short-term investments on hand.  In the future, the Company will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, product sales and funded research and development programs to maintain the Company's operations and meet the Company's obligations. There is no guarantee that additional equity or other financings will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back, terminate its operations or seek to merge with or be acquired by another company. Management believes that the Company's existing cash resources will be sufficient to fund the Company's operations into at least the second half of 2023.</p>
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-486073000
CY2021Q1 rytm Proceeds From Sale Of Priority Review Voucher
ProceedsFromSaleOfPriorityReviewVoucher
100000000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
328354000
CY2020Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
63000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates relied upon in preparing these financial statements include accruals related to research and development expenses, assumptions used to record stock-based compensation expense and the valuation allowance on the Company's deferred tax assets.  Estimates are periodically reviewed in light of changes in circumstances, facts and experience.  Changes in estimates are recorded in the period in which they become known.  Actual results could differ materially from those estimates.</p>
rytm Number Of Federally Insured Financial Institutions
NumberOfFederallyInsuredFinancialInstitutions
2
rytm Number Of Federally Insured Financial Institutions
NumberOfFederallyInsuredFinancialInstitutions
2
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
rytm Revenue Performance Obligation Payment Terms
RevenuePerformanceObligationPaymentTerms
P45D
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1028000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1337000
rytm Accounts Receivable Terms
AccountsReceivableTerms
P45D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5275914
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6406621
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5275914
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6406621
CY2021Q3 rytm Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
8943000
CY2020Q4 rytm Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
5815000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2560000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
648000
CY2021Q3 rytm Accrued Payroll Related Expense Current
AccruedPayrollRelatedExpenseCurrent
6008000
CY2020Q4 rytm Accrued Payroll Related Expense Current
AccruedPayrollRelatedExpenseCurrent
5916000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
754000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
180000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18265000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12559000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
328354000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
172792000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
235961000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
235982000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
71895000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
43000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
71938000
CY2021Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y9M18D
CY2021Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P6Y
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
203000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
818000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
834000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
851000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
502000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3208000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
516000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2692000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
455000
CY2021Q3 rytm Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
2838000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4772000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4772000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
114000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
455000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
455000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
455000
us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P11Y
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
114000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
228000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8995000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7989000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000
CY2021Q1 us-gaap Share Price
SharePrice
30.00
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161731000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
2811000

Files In Submission

Name View Source Status
0001558370-21-014043-index-headers.html Edgar Link pending
0001558370-21-014043-index.html Edgar Link pending
0001558370-21-014043.txt Edgar Link pending
0001558370-21-014043-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rytm-20210930.xsd Edgar Link pending
rytm-20210930x10q.htm Edgar Link pending
rytm-20210930x10q_htm.xml Edgar Link completed
rytm-20210930xex10d2.htm Edgar Link pending
rytm-20210930xex10d2001.jpg Edgar Link pending
rytm-20210930xex31d1.htm Edgar Link pending
rytm-20210930xex31d2.htm Edgar Link pending
rytm-20210930xex32d1.htm Edgar Link pending
rytm-20210930xex32d2.htm Edgar Link pending
rytm-20210930xex4d1.htm Edgar Link pending
rytm-20210930_cal.xml Edgar Link unprocessable
rytm-20210930_def.xml Edgar Link unprocessable
rytm-20210930_lab.xml Edgar Link unprocessable
rytm-20210930_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending